These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28553080)

  • 1. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.
    Borrás Pérez MV; Kriström B; Romer T; Walczak M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1497-1503. PubMed ID: 28553080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
    López-Siguero JP; Pfäffle R; Chanson P; Szalecki M; Höbel N; Zabransky M
    Drug Des Devel Ther; 2017; 11():1489-1495. PubMed ID: 28553079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten years of biosimilar recombinant human growth hormone in Europe.
    Saenger P
    Drug Des Devel Ther; 2017; 11():1505-1507. PubMed ID: 28553081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
    Schiestl M; Zabransky M; Sörgel F
    Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
    Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
    Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
    BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
    Höybye C; Beck-Peccoz P; Murray RD; Simsek S; Stalla G; Strasburger CJ; Urosevic D; Zouater H; Johannsson G
    Pituitary; 2021 Aug; 24(4):622-629. PubMed ID: 33742320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice].
    López-Siguero JP; Palla García M; Martínez Busto E; Rebollo FJ; Pombo M
    An Pediatr (Engl Ed); 2018 Apr; 88(4):209-215. PubMed ID: 28668339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
    Beck-Peccoz P; Höybye C; Murray RD; Simsek S; Zabransky M; Zouater H; Stalla G
    BMC Endocr Disord; 2019 Dec; 19(1):138. PubMed ID: 31829160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
    Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
    J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing switchability for biosimilar products: modelling approaches applied to children's growth.
    Belleli R; Fisch R; Renard D; Woehling H; Gsteiger S
    Pharm Stat; 2015; 14(4):341-9. PubMed ID: 25989222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
    Borrás Pérez V; López-Siguero JP; Martínez G; Corripio R; Fernández JM; Labarta JI; Ferrer M; Cabrinety N; Prieto P; Ramón-Krauel M; Bosch J; Espino R; Palla Garcia M; Rebollo FJ
    Adv Ther; 2015 Feb; 32(2):148-56. PubMed ID: 25667132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis.
    Stanhope R; Sörgel F; Gravel P; Pannatier Schuetz YB; Zabransky M; Muenzberg M
    J Clin Pharmacol; 2010 Nov; 50(11):1339-48. PubMed ID: 20173088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of Omnitrope
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    Eur J Pediatr; 2022 Jun; 181(6):2367-2378. PubMed ID: 35275291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety concerns of biosimilar hormone products.
    Soldatov AA; Avdeeva JI; Kryuchkov NA; Skosyreva ES
    Curr Med Res Opin; 2019 Jun; 35(6):1003-1009. PubMed ID: 30466327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden.
    Flodmark CE; Lilja K; Woehling H; Järvholm K
    Biol Ther; 2013; 3(1):35-43. PubMed ID: 24392303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Pfäffle RW; Höybye C; Lundberg E; Battelino T; Kriström B; Giemza T; Zouater H
    Horm Res Paediatr; 2021; 94(3-4):133-143. PubMed ID: 34350858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.